Christopher J Walker1, Mario A Miranda1, Matthew J O'Hern1, Joseph P McElroy1, Kevin R Coombes1, Ralf Bundschuh1, David E Cohn1, David G Mutch1, Paul J Goodfellow2. 1. Department of Obstetrics and Gynecology, Division of Gynecology Oncology (CJW, MAM, MJO, DEC, PJG), Department of Biomedical Informatics, Center for Biostatistics, College of Medicine (JPM, KRC), The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (CJW, MAM, MJO, JPM, KRC, DEC, PJG), Department of Physics, Department of Chemistry & Biochemistry, Department of Internal Medicine, Division of Hematology, Center for RNA Biology (RB), The Ohio State University, Columbus, OH; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Washington University, St. Louis, MO (DGM). 2. Department of Obstetrics and Gynecology, Division of Gynecology Oncology (CJW, MAM, MJO, DEC, PJG), Department of Biomedical Informatics, Center for Biostatistics, College of Medicine (JPM, KRC), The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (CJW, MAM, MJO, JPM, KRC, DEC, PJG), Department of Physics, Department of Chemistry & Biochemistry, Department of Internal Medicine, Division of Hematology, Center for RNA Biology (RB), The Ohio State University, Columbus, OH; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Washington University, St. Louis, MO (DGM). paul.goodfellow@osumc.edu.
Abstract
BACKGROUND: The genetic events responsible for tumor aggressiveness in endometrioid endometrial cancer (EEC) remain poorly understood. The chromosome 16q22 tumor suppressor genes CTCF and ZFHX3 are both frequently mutated in EEC, but their respective roles in outcome have not been determined. METHODS: Targeted deep sequencing of CTCF and ZFHX3 was performed for 542 EEC samples. Copy number loss (CNL) was determined using microsatellite typing of paired tumor and normal DNA and a novel Bayesian method based on variant allele frequencies of germline polymorphisms. All statistical tests were two-sided. RESULTS: Mutation rates for CTCF and ZFHX3 were 25.3% and 20.4%, respectively, and there was a statistically significant excess of tumors with mutation in both genes (P = .003). CNL rates were 17.4% for CTCF and 17.2% for ZFHX3, and the majority of CNLs included both CTCF and ZFHX3. Mutations were more frequent in tumors with microsatellite instability, and CNLs were more common in microsatellite-stable tumors (P < .001). Patients with ZFHX3 mutation and/or CNL had higher-grade tumors (P = .001), were older (P < .001), and tended to have more frequent lymphovascular space invasion (P = .07). These patients had reduced recurrence-free and overall survival (RFS: hazard ratio [HR] = 2.35, 95% confidence interval [CI] = 1.38 to 3.99, P = .007; OS: HR = 1.51, 95% CI = 1.11 to 2.07, P = .04). CONCLUSIONS: Our data demonstrate there is strong selection for inactivation of both CTCF and ZFHX3 in EEC. Mutation occurs at high frequency in microsatellite-unstable tumors, whereas CNLs are common in microsatellite-stable cancers. Loss of these two tumor suppressors is a frequent event in endometrial tumorigenesis, and ZFHX3 defects are associated with poor outcome.
BACKGROUND: The genetic events responsible for tumor aggressiveness in endometrioid endometrial cancer (EEC) remain poorly understood. The chromosome 16q22 tumor suppressor genes CTCF and ZFHX3 are both frequently mutated in EEC, but their respective roles in outcome have not been determined. METHODS: Targeted deep sequencing of CTCF and ZFHX3 was performed for 542 EEC samples. Copy number loss (CNL) was determined using microsatellite typing of paired tumor and normal DNA and a novel Bayesian method based on variant allele frequencies of germline polymorphisms. All statistical tests were two-sided. RESULTS: Mutation rates for CTCF and ZFHX3 were 25.3% and 20.4%, respectively, and there was a statistically significant excess of tumors with mutation in both genes (P = .003). CNL rates were 17.4% for CTCF and 17.2% for ZFHX3, and the majority of CNLs included both CTCF and ZFHX3. Mutations were more frequent in tumors with microsatellite instability, and CNLs were more common in microsatellite-stable tumors (P < .001). Patients with ZFHX3 mutation and/or CNL had higher-grade tumors (P = .001), were older (P < .001), and tended to have more frequent lymphovascular space invasion (P = .07). These patients had reduced recurrence-free and overall survival (RFS: hazard ratio [HR] = 2.35, 95% confidence interval [CI] = 1.38 to 3.99, P = .007; OS: HR = 1.51, 95% CI = 1.11 to 2.07, P = .04). CONCLUSIONS: Our data demonstrate there is strong selection for inactivation of both CTCF and ZFHX3 in EEC. Mutation occurs at high frequency in microsatellite-unstable tumors, whereas CNLs are common in microsatellite-stable cancers. Loss of these two tumor suppressors is a frequent event in endometrial tumorigenesis, and ZFHX3 defects are associated with poor outcome.
Authors: Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson Journal: Genome Res Date: 2012-02-02 Impact factor: 9.043
Authors: William Stedman; Hyojeung Kang; Shu Lin; Joseph L Kissil; Marisa S Bartolomei; Paul M Lieberman Journal: EMBO J Date: 2008-01-24 Impact factor: 11.598
Authors: S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton Journal: Curr Protoc Hum Genet Date: 2008-04
Authors: Nicole L Solimini; Qikai Xu; Craig H Mermel; Anthony C Liang; Michael R Schlabach; Ji Luo; Anna E Burrows; Anthony N Anselmo; Andrea L Bredemeyer; Mamie Z Li; Rameen Beroukhim; Matthew Meyerson; Stephen J Elledge Journal: Science Date: 2012-05-24 Impact factor: 47.728
Authors: Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly Journal: Nat Genet Date: 2011-04-10 Impact factor: 38.330
Authors: Floor J Backes; Christopher J Walker; Paul J Goodfellow; Erinn M Hade; Garima Agarwal; David Mutch; David E Cohn; Adrian A Suarez Journal: Gynecol Oncol Date: 2016-03-10 Impact factor: 5.482
Authors: Christopher J Walker; Mario A Miranda; Matthew J O'Hern; James S Blachly; Cassandra L Moyer; Jennifer Ivanovich; Karl W Kroll; Ann-Kathrin Eisfeld; Caroline E Sapp; David G Mutch; David E Cohn; Ralf Bundschuh; Paul J Goodfellow Journal: Hum Mutat Date: 2016-08-08 Impact factor: 4.878
Authors: Christopher J Walker; Craig M Rush; Paola Dama; Matthew J O'Hern; Casey M Cosgrove; Jessica L Gillespie; Roman A Zingarelli; Blair Smith; Maggie E Stein; David G Mutch; Reena Shakya; Chia-Wen Chang; Karuppaiyah Selvendiran; Jonathan W Song; David E Cohn; Paul J Goodfellow Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: A D Marshall; C G Bailey; K Champ; M Vellozzi; P O'Young; C Metierre; Y Feng; A Thoeng; A M Richards; U Schmitz; M Biro; R Jayasinghe; L Ding; L Anderson; E R Mardis; J E J Rasko Journal: Oncogene Date: 2017-03-20 Impact factor: 9.867
Authors: Christopher J Walker; Matthew J O'Hern; Vanida A Serna; Takeshi Kurita; Mario A Miranda; Caroline E Sapp; David G Mutch; David E Cohn; Paul J Goodfellow Journal: Oncotarget Date: 2017-08-12